Biomarkers For Alzheimers

Biomarkers for Alzheimer's Disease (AD) are critical for early diagnosis, tracking disease progression, and evaluating treatment efficacy. Key biomarkers include amyloid-beta (Aβ) plaques, tau protein tangles, and neurodegeneration indicators. Aβ plaques, detectable through cerebrospinal fluid (CSF) analysis and PET scans, signify early AD stages. Elevated levels of tau protein and phosphorylated tau in CSF correlate with neurofibrillary tangles, reflecting disease severity. Neurodegeneration markers, such as reduced glucose metabolism observed via FDG-PET scans and brain atrophy seen in MRI scans, indicate neuronal loss and cognitive decline. Novel blood-based biomarkers, including plasma Aβ and tau, offer non-invasive, cost-effective alternatives for widespread screening and monitoring. These advancements promise earlier intervention and improved management of AD and related dementias.